Integrated Filing — IndAS



General information about company

Scrip Code 524558
NSE Symbol NEULANDLAB
MSEI Symbol NOTLISTED
ISIN INE794A01010
Name of company NEULAND LABORATORIES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 03-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 22-10-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Manufacturing of Active Pharmaceuticals
Start date and time of board meeting 03-11-2026   09:30:00
End date and time of board meeting 03-11-2026   15:34:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 44,965.69 1,09,123.40
Other income 749.53 1,598.70
Total income 45,715.22 1,10,722.10
2 Expenses
(a) Cost of materials consumed 21,578.73 44,455.65
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (6,473.15) (7,247.69)
(d) Employee benefit expense 10,175.87 20,818.79
(e) Finance costs 730.73 1,427.92
(f) Depreciation, depletion and amortisation expense 2,877.13 5,533.45
(f) Other Expenses
1 Manufacturing expenses 5,780.43 10,574.00
2 Other expenses 4,147.66 8,477.46
Total other expenses 9,928.09 19,051.46
Total expenses 38,817.40 84,039.58
3 Total profit before exceptional items and tax 6,897.82 26,682.52
4 Exceptional items 0.00 0.00
5 Total profit before tax 6,897.82 26,682.52
6 Tax expense
7 Current tax 1,786.79 6,874.82
8 Deferred tax (51.47) (122.11)
9 Total tax expenses 1,735.32 6,752.71
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 5,162.50 19,929.81
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 5,162.50 19,929.81
17 Other comprehensive income net of taxes (35.12) (44.02)
18 Total Comprehensive Income for the period 5,127.38 19,885.79
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 5,162.70 19,929.81
Total profit or loss, attributable to non-controlling interests 0.00 0.00
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 5,127.38 19,885.79
Total comprehensive income for the period attributable to owners of parent non-controlling interests 0.00 0.00
21 Details of equity share capital
Paid-up equity share capital 1,290.05 1,290.05
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 40.24 155.34
Diluted earnings (loss) per share from continuing operations 40.24 155.34
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 40.24 155.34
Diluted earnings (loss) per share from continuing and discontinued operations 40.24 155.34
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The financial results for the quarter and half year ended September 30, 2026, have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 03, 2026.The Statutory auditor have issued an unmodified opinion in respect of the limited review for the quarter and half year ended September 30, 2026. 2. The financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34, Interim Financial Reporting, prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India, and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 3. The consolidated financial results include results of the following wholly owned subsidiaries: (a) Neuland Laboratories Inc., USA (b) Neuland Laboratories KK., Japan. 4. Segment Reporting i. Segment information presented for the Consolidated financial results as permitted under the Ind AS - 'Operating Segments'. ii. The management has assessed the identification of reportable segments in accordance with the requirements of Ind AS 108 ‘Operating Segment’ and believes that the Group has only one reportable segment namely manufacture of active pharmaceutical ingredients and allied services”. Geography-wise details of the Company’s revenues from external customers and its non-current assets (excluding financial assets) are disclosed above. 5. The EPS for quarters has not been annualised.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 99,419.13
Capital work-in-progress 28,429.54
Investment property 0.00
Goodwill 27,946.10
Other intangible assets 386.16
Intangible assets under development 45.64
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 198.22
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets
1 Security deposits 1,390.02
Total of other non-current financial assets 1,390.02
Total non-current financial assets 1,588.24
Deferred tax assets (net) 0.00
Other non-current assets
1 Prepaid expenses 18.89
2 Capital advances (Refer Note 40) 5,897.23
3 Balances with government authorities 23.37
4 Income tax assets (net) 216.23
Total of other non-current assets 6,155.72
Total non-current assets 1,63,970.53
2 Current assets
Inventories 55,210.02
Current financial asset
Current investments 0.00
Trade receivables, current 29,430.40
Cash and cash equivalents 5,365.54
Bank balance other than cash and cash equivalents 39,678.28
Loans, current 0.00
Other current financial assets
Total of other current financial assets 1,454.36
Total current financial assets 75,928.58
Current tax assets (net) 0.00
Other current assets
1 Prepaid expenses 2,113.83
2 Advance to suppliers 1,793.81
3 Balances with government authorities 3,147.30
4 Export benefits receivable 791.76
Total of other current assets 7,846.70
Total current assets 1,38,985.30
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 3,02,955.83
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1,290.05
Other equity 2,01,680.91
Total equity attributable to owners of parent 2,02,970.96
Non controlling interest 0.00
Total equity 2,02,970.96
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 29,633.12
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
Total of other non-current financial liabilities
Total non-current financial liabilities 29,633.12
Provisions, non-current 1,694.86
Deferred tax liabilities (net) 6,799.25
Deferred government grants, Non-current 0.00
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 38,127.23
Current liabilities
Current financial liabilities
Borrowings, current 4,597.60
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 1,451.79
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 19,409.83
Total Trade payable 20,861.62
Other current financial liabilities
1 Interest accrued but not due on borrowings 3.97
2 Interest accrued on micro enterprises and small enterprises payable 12.12
3 Unclaimed dividends 21.73
4 Capital creditors 2,091.84
5 Employee benefits payable (Refer Note 39) 3,016.36
6 Accrual for expenses 6,120.58
Total of other current financial liabilities 11,266.60
Total current financial liabilities 36,725.82
Other current liabilities 23,630.11
1 Advance from customers 22,667.34
2 Liability towards Corporate Social Responsibility ('CSR') expenditure 179.68
3 Statutory liabilities 783.09
Total of other current liabilities 23,630.11
Provisions, current 309.37
Current tax liabilities (Net) 1,192.34
Deferred government grants, Current 0.00
Total current liabilities 61,857.64
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 99,984.87
Total equity and liabilites 3,02,955.83
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Re-measurement gain on defined benefit plans (27.57) (27.57)
Total Amount of items that will not be reclassified to profit and loss (27.57) (27.57)
2 Income tax relating to items that will not be reclassified to profit or loss (6.94) (6.94)
3 Amount of items that will be reclassified to profit and loss
1 Exchange differences in translating the financial statements of foreign operations (14.49) (23.39)
Total Amount of items that will be reclassified to profit and loss (14.49) (23.39)
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income (35.12) (44.02)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 26,682.52
Adjustments for reconcile profit (loss)
Adjustments for finance costs 1,427.93
Adjustments for decrease (increase) in inventories (4,181.38)
Adjustments for decrease (increase) in trade receivables, current 24,608.84
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (627.66)
Adjustments for decrease (increase) in other non-current assets (3.52)
Adjustments for other financial assets, non-current (195.20)
Adjustments for other financial assets, current (316.93)
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current (5,874.42)
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (1,687.65)
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 5,533.45
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 159.77
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current (392.12)
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (365.39)
Adjustments for dividend income 0.00
Adjustments for interest income 1,598.62
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 235.40
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 37.09
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 16,759.59
Net cash flows from (used in) operations 43,442.11
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 7,286.06
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 36,156.05
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 22.05
Purchase of property, plant and equipment 26,059.89
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 896.55
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (11,850.38)
Net cash flows from (used in) investing activities (36,991.67)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 6,794.04
Repayments of borrowings 2,289.53
Payments of lease liabilities 155.56
Dividends paid 4,362.17
Interest paid 959.72
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (470.12)
Net cash flows from (used in) financing activities (1,443.06)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (2,278.68)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents (22.82)
Net increase (decrease) in cash and cash equivalents (2,301.50)
Cash and cash equivalents cash flow statement at beginning of period 7,667.04
Cash and cash equivalents cash flow statement at end of period 5,365.54





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 M S K A & Associates LLP, Chartered Accountants Yes 31-07-2027